Glycostem’s oNKord Cell-based Therapy Granted FDA Orphan Drug Designation

Home / Blog / Glycostem’s oNKord Cell-based Therapy Granted FDA Orphan Drug Designation
Glycostem’s oNKord Cell-based Therapy Granted FDA Orphan Drug Designation
October 17, 2020October 17, 2020
0

The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to oNKord, Glycostem Therapeutics‘ cell-based therapy for the treatment of multiple myeloma, the company announced in a press release. This designation is awarded to potential therapies that prevent, diagnose, or treat conditions that affect fewer than 200,000 people in the U.S. It provides several development incentives to bring a product quickly to market. These incentives include guidance from the regulatory agency on…

You must be logged in to read/download the full post.

The post Glycostem’s oNKord Cell-based Therapy Granted FDA Orphan Drug Designation appeared first on BioNewsFeeds.